İrem UZUN -TDO- U.S. drugmaker Pfizer said Monday that human trials suggest its coronavirus vaccine is 90% effective at preventing COVID-19 infections in people not known to have had the virus already. "Today is a great day for science and humanity. The first set of results from our Phase 3 COVID-19 vaccine trial provides the initial evidence of our vaccine's ability to prevent COVID-19," Dr. Albert Bourla, Pfizer Chairman and CEO, said in a statement.
The vaccine is the first to be tested in the United States to generate late-stage data. The companies said an early analysis of the results showed that individuals who received two injections of the vaccine three weeks apart experienced more than 90% fewer cases of symptomatic COVID-19 than those who received a placebo. For months, researchers have cautioned that a vaccine that might only be 60% or 70% effective. The Phase 3 study is ongoing and additional data could affect results. Pfizer said it would be applying for Emergency Use Authorization from the FDA as soon as final data meets safety milestones, which it expects to happen in the third week of November.
The World Health Organization (WHO) chief Tedros Adhanom Ghebreyesus hailed as "encouraging" Pfizer’s announcement on Monday. "We welcome the encouraging vaccine news from Pfizer & BioNTech Group and salute all scientists and partners around the who are developing new safe, efficacious tools to beat COVID19," Tedros said on Twitter.